Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference.
The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target appeared first on MedCity News.
